Biology:Self-protein

From HandWiki
Revision as of 15:12, 12 February 2024 by LinXED (talk | contribs) (fixing)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Self-protein refers to all proteins endogenously produced by DNA-level transcription and translation within an organism of interest. This does not include proteins synthesized due to viral infection, but may include those synthesized by commensal bacteria within the intestines. Proteins that are not created within the body of the organism of interest, but nevertheless enter through the bloodstream, a breach in the skin, or a mucous membrane, may be designated as “non-self” and subsequently targeted and attacked by the immune system. Tolerance to self-protein is crucial for overall wellbeing; when the body erroneously identifies self-proteins as “non-self”, the subsequent immune response against endogenous proteins may lead to the development of an autoimmune disease.[1][2]

Examples

Proteins targeted by the immune system Resulting autoimmune disease
Thyroid stimulating hormone receptor Graves' disease[3]
Pancreatic beta-cell proteins Type 1 diabetes mellitus[4]
Commensal bacteria flagellum Inflammatory bowel disease[5]
Nuclear and cell membrane phospholipids Lupus[6]
Tissue transglutaminase Celiac disease[7]

Of note, the list provided above is not exhaustive; the list does not mention all possible proteins targeted by the provided autoimmune diseases.

Identification by the immune system

Autoimmune responses and diseases are primarily instigated by T lymphocytes that are incorrectly screened for reactivity to self-protein during cell development.[citation needed]

During T-cell development, early T-cell progenitors first move via chemokine gradients from the bone marrow into the thymus, where T-cell receptors are randomly rearranged at the gene level to allow for T-cell receptor generation.[8] These T-cells have the potential to bind to anything, including self-proteins.[citation needed]

The immune system must differentiate the T-cells that have receptors capable of binding to self versus non-self proteins; T-cells that can bind to self-proteins must be destroyed to prevent development of an autoimmune disorder. In a process known as “Central Tolerance”, T-cells are exposed to cortical epithelial cells that express a variety of different major histocompatibility complexes (MHC) of both class 1 and class 2, which have the ability to bind to T-cell receptors of CD8+ cytotoxic T-cells, and CD4+ helper T-cells, respectively. The T-cells that display affinity for these MHC are positively selected to continue to the second stage of development, while those that cannot bind to MHC undergo apoptosis.[9] In the second stage, immature T-cells are exposed to a variety of macrophages, dendritic cells, and medullary epithelial cells that express self-protein on MHC class 1 and class 2. These epithelial cells also express the transcription factor labelled autoimmune regulator (AIRE) - this crucial transcription factor allows the medullary epithelial cells of the thymus to express proteins would normally be present in peripheral tissue rather than in an epithelial cell, such as insulin-like peptides, myelin-like peptides, and more.[10] As these epithelial cells now present a large variety of self-proteins that could be encountered across the body, the immature T-cells are tested for affinity to self-protein and self-MHC. If any T-cell has strong affinity for self-protein and self-MHC, the cell undergoes apoptosis to prevent autoimmune function.[9] T-cells that display low/medium affinity are allowed to leave the thymus and circulate throughout the body to react to novel non-self antigen. In this manner, the body attempts to systematically destroy T-cells that could lead to autoimmunity.[citation needed]

References

  1. "Mechanisms of human autoimmunity". The Journal of Clinical Investigation 125 (6): 2228–33. June 2015. doi:10.1172/JCI78088. PMID 25893595. 
  2. "Cellular and Molecular Mechanisms of Autoimmunity and Lupus Nephritis". International Review of Cell and Molecular Biology (Elsevier) 332: 43–154. 2017. doi:10.1016/bs.ircmb.2016.12.001. ISBN 978-0-12-812471-0. PMID 28526137. 
  3. "Graves' Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies". Hormone and Metabolic Research 47 (10): 727–34. September 2015. doi:10.1055/s-0035-1559633. PMID 26361259. 
  4. "Antigen targets of type 1 diabetes autoimmunity". Cold Spring Harbor Perspectives in Medicine 2 (4): a007781. April 2012. doi:10.1101/cshperspect.a007781. PMID 22474615. 
  5. "Antibody markers in the diagnosis of inflammatory bowel disease". World Journal of Gastroenterology 22 (3): 1304–10. January 2016. doi:10.3748/wjg.v22.i3.1304. PMID 26811667. 
  6. "Key autoantigens in SLE". Rheumatology 44 (8): 975–82. August 2005. doi:10.1093/rheumatology/keh688. PMID 15901907. 
  7. "Antibodies in celiac disease: implications beyond diagnostics". Cellular & Molecular Immunology 8 (2): 103–9. March 2011. doi:10.1038/cmi.2010.65. PMID 21278768. 
  8. "Progenitor migration to the thymus and T cell lineage commitment". Immunologic Research 42 (1–3): 65–74. 2008-09-16. doi:10.1007/s12026-008-8035-z. PMID 18827982. 
  9. 9.0 9.1 "T-cell tolerance: central and peripheral". Cold Spring Harbor Perspectives in Biology 4 (6): a006957. June 2012. doi:10.1101/cshperspect.a006957. PMID 22661634. 
  10. "Aire and T cell development". Current Opinion in Immunology 23 (2): 198–206. April 2011. doi:10.1016/j.coi.2010.11.007. PMID 21163636.